Psychological Risks of Cosmetic Procedures: The Consent Gap the Industry Won't Talk About

In 2001, the New York Court of Appeals sided with Dr Norman Hugo in a case that should have sent shockwaves through the aesthetic medicine industry, but largely didn't. We covered the Lynn G v Hugo case in more detail in a previous piece, but the short version is this: Lynn G v Hugo was not a story about surgical error. It was about a long-term patient, a trusted, prominent surgeon, a routine procedure with a typical result, and a complaint that had nothing to do with anything going objectively wrong. Lynn G claimed she suffered from Body Dysmorphic Disorder (BDD) and that Dr Hugo should have identified it and referred her for psychiatric evaluation before proceeding. He did not, and she sued.

After a long battle, Hugo won, narrowly and luckily. The aesthetic industry logged it as a win and moved on. It left behind an uncomfortable question nobody has thought to ask since then: what would a BDD-based consent argument look like today?

Body Dysmorphic Disorder (BDD) is not the obscure fringe diagnosis it was in the nineties. It is now classified under obsessive-compulsive and related disorders in DSM-5, has a substantial and growing body of clinical literature behind it, and is increasingly recognised in medical and legal contexts. A court hearing the same facts in 2026 would be doing so in a very different landscape. The argument that a surgeon should have been aware of BDD, or at minimum should have disclosed its relevance to a patient seeking repeated cosmetic procedures, is considerably harder to dismiss now than it was then.

Consider a hypothetical that is not particularly far-fetched. A patient undergoes a cosmetic procedure. The outcome is clinically unremarkable. The patient is dissatisfied, not because anything went wrong, but because the procedure did not relieve the distress they felt about their appearance. They were never told that this was a known and documented risk. They were never told that for a subset of cosmetic patients, treatment is unlikely to resolve appearance-related distress and may leave it worse. They were never warned about BDD at all. They file a claim on the basis of inadequate informed consent. That claim has legs. And here is why.

Informed consent in cosmetic practice routinely covers physical risks: scarring, infection, asymmetry, vascular occlusion, allergic reaction. Patients are warned about complications that, in many cases, are relatively uncommon. Allergic reactions to commonly used products are rare, yet disclosure is standard. No practitioner would consider omitting it. So why are the psychological risks of cosmetic procedures still left out of consent?

Why the Psychological Risks of Cosmetic Procedures Belong In Informed Consent

BDD is estimated to affect somewhere between 19% and 24% of cosmetic surgery patients. That is roughly one in five. It is associated with poor satisfaction after treatment and poor psychological outcomes. It is not a remote possibility to be noted in passing. It is a known, documented, and prevalent risk in this specific patient population. Yet the psychological risks of cosmetic procedures are almost never disclosed as part of the informed consent process.

The parallel is uncomfortable. A practitioner cannot identify an unknown allergy in advance. They cannot run every patient through an allergy panel before treatment. What they can do is warn the patient, document that warning, and ensure the patient has engaged with the information before proceeding. That protection exists for allergies. It does not exist for BDD.

The argument that practitioners cannot be expected to screen for or diagnose BDD is entirely valid. That is not what is being asked. The question is whether patients have a right to be told that a condition affecting a significant proportion of people seeking the same treatment may mean they are unlikely to benefit from it. Framed that way, the answer seems obvious.

Lynn G v Hugo was decided at a time when BDD was poorly understood and rarely discussed in cosmetic contexts. That time has passed. The clinical evidence has accumulated. The legal conversation is catching up, and the industry has a narrowing window to get ahead of it.

The solution is not screening. Practitioners are not qualified to assess psychological suitability and should not be expected to. The solution is disclosure. Patients are told about scarring. They are told about infection. They are told about asymmetry.

A condition estimated to affect one in five of them, and strongly associated with poor outcomes after treatment, does not feature in the consent process at all. That is not a gap. It is an oversight the industry can no longer justify.